Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Paradigm Biopharmaceuticals Achieves First Revenue

19 May 2021  |  09:09:00  |  Associate analysts  |  Increase  |  Decrease  |  


Paradigm Biopharmaceuticals announces that it has received first revenue through a physician prescription of Zilosul to patients via the TGA SAS. In Australia, injectable Pentosan Polysulfate Sodium (iPPS/Zilosul) is not currently available for sale. Injectable PPS for human use is only available to patients who qualify for inclusion into a Paradigm Sponsored clinical trial or via a treating physician applying for its use in patients via the TGA's SAS (Category B).

Please click here for full details

See more ASX300 News Announcements